Panel Discussion: Defining a Unified Path Towards IVDR Compliance for Streamlined Approvals
- How has IVDR changed expectations for evidence generation, documentation, and timelines across regulators, notified bodies, pharma, and diagnostic developers?
- At what stage should pharma and diagnostic partners meaningfully engage notified bodies and regulators to ensure an aligned CDx development pathway? And what does effective early alignment look like?
- What are the most common bottlenecks companies encounter during IVDR certification, and what practical steps or partnership models are proving successful in navigating them?